

CALIFORNIA CANCER REGISTRY

DATA STANDARDS AND QUALITY CONTROL UNIT

Memorandum

DSQC Memo #2012-02

CATEGORY: Clarification

SUBJECT: Breast Schema
SSF 21 Response to Neoadjuvant Therapy
CS Tumor Size/Ext Eval
Lymph Nodes Eval

EFFECTIVE: Cases Diagnosed 01/01/2012 and forward
and Any Cases Entered After the Installation of
CSv02.04 Software

The Collaborative Stage (CS) Manual defines neoadjuvant therapy as systemic therapy or radiation treatment administered prior to surgery in an attempt to shrink the tumor or destroy regional metastases. CS Site-Specific Factor 21 in the breast schema documents whether that neoadjuvant therapy was successful. The following will assist registrars in coding SSF 21 and the associated CS Tumor Size/Ext Eval and CS Lymph Nodes Eval fields:

- Use code 987 when no neoadjuvant therapy was given.
 - This code also includes cases that were not treated with neoadjuvant therapy, but systemic therapy or radiation treatment was given after surgery.
- Use code 999 when:
 - Neoadjuvant was given and there is no statement of complete, partial or no response by the clinician, or when the response is not documented in the medical record.
 - It is unknown if neoadjuvant therapy was given.
 - Do not try to interpret or infer a response based on other documentation in the medical record such as a description of residual tumor on the pathology report.
- When SSF 21 is coded 010, 020, 025*, 030 (received neoadjuvant therapy), then either CS Tumor Size/Ext Eval or

CS Lymph Nodes Eval must be coded 5 or 6 indicating the patient received neoadjuvant therapy. (Volume III, Edit IF420).

- For CS Lymph Nodes Eval, if lymph node dissection is not performed after neoadjuvant therapy, use code 0 or 1.
- When SSF 21 is coded 987, then CS Tumor Size/Ext Eval and CS Lymph Nodes Eval must not be coded 5 or 6. (Volume III, Edit IF421).

*Code 025 added to CSv02.04

References: Collaborative Stage General Instructions,
Part I Section 2: Site-Specific Notes

Collaborative Stage Staging and Coding Rules
Manual, Breast Schema CSv02.04

California Cancer Reporting Standards: Volume III
(Revised 1/5/2012)

Note: In accordance with the 2010 Visual Editing Standards, discrepancies are not currently being counted for the Collaborative Stage site specific factors. However, feedback will be based on adherence to this memo effective 30 days from the distribution date.

Distribution Date: April 10, 2012

California Cancer Registry

[Forward email](#)



This email was sent to kvance@ccr.ca.gov by kvance@ccr.ca.gov |
[Update Profile/Email Address](#) | Instant removal with [SafeUnsubscribe™](#) | [Privacy Policy](#).

Public Health Institute | 1825 Bell Street | Suite 102 | Sacramento | CA | 95825